THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Amgen AMGN reported third-quarter 2024 adjusted earnings of ... Lumakras/Lumykras recorded sales of $98 million in the quarter, up 88% from the year-ago period. Imdelltra (tarlatamab), approved for ...

Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - ...

Get the latest updates on Amgen's upcoming Q3 earnings results, including insights from analysts on key products and trial ...

Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, ...

Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products ...

A previously healthy 9-year-old Latina girl presented in the last week of December 2001 to the Children's Hospital Los Angeles emergency room with a 4-day history of severe headache and fever of ...